Seroquel (quetiapine) is used for depression, but the specifics matter. The FDA has approved it for depressive episodes in bipolar disorder, where it works as a standalone treatment. For major depressive disorder (the more common, non-bipolar form), Seroquel does not have FDA approval, though the extended-release version is sometimes prescribed off-label as an add-on when standard antidepressants haven’t worked well enough. The doses used for depression are also much lower than those used for conditions like schizophrenia.
What Seroquel Is Officially Approved For
The FDA has approved Seroquel for three conditions: schizophrenia, manic episodes in bipolar I disorder, and depressive episodes in bipolar disorder. That last indication is the only depression-related approval, and it covers bipolar depression specifically, not standard major depressive disorder (MDD).
Despite the lack of formal approval for MDD, prescribers frequently use quetiapine’s extended-release form as an add-on to antidepressants when patients haven’t responded adequately. This is considered off-label use. Mayo Clinic’s dosing guidelines list MDD as a use for the extended-release tablet, starting at 50 mg once daily in the evening and typically capping at 300 mg per day. That ceiling is notably lower than the 800 mg maximum used for schizophrenia or bipolar mania.
How It Works Differently Than Antidepressants
Seroquel is classified as an atypical antipsychotic, not an antidepressant, but it affects several of the same brain pathways. Its antidepressant properties are thought to come from two actions: it blocks serotonin receptors that can dampen mood, and it partially activates a different serotonin receptor (5-HT1A) that’s also targeted by some anxiety and depression medications. It actually binds to serotonin receptors more strongly than to dopamine receptors, which sets it apart from older antipsychotics.
At low doses, Seroquel primarily occupies histamine and certain serotonin receptors, which is why small amounts produce heavy sedation and sleep benefits before the antipsychotic effects kick in at higher doses. This layered receptor profile is why the same drug gets prescribed at 25 mg for sleep, 150 mg for depression, and 600 mg for psychosis.
How Well It Works for Depression
The evidence for quetiapine in depression is solid but not overwhelming. A 2025 head-to-head trial (the LQD study) compared quetiapine to lithium as add-on treatments for people whose depression hadn’t responded to antidepressants alone. Quetiapine outperformed lithium on depression scores, with patients also showing significantly better social functioning. However, remission rates between the two groups were statistically similar.
A 2022 systematic review comparing quetiapine to other atypical antipsychotics used as add-on depression treatments found it performed comparably to aripiprazole, brexpiprazole, olanzapine, and several others. None showed a clear advantage over quetiapine, and quetiapine didn’t clearly beat them either. In practical terms, it’s one of several reasonable options when first-line antidepressants fall short, and the choice often comes down to side effect profiles and individual response.
The Sleep Connection
One reason Seroquel is popular for depression is that it pulls double duty by improving sleep. A systematic review and meta-analysis of clinical trials found that quetiapine significantly improved sleep quality in people with MDD, generalized anxiety disorder, and even healthy volunteers. The effect was present across doses of 50 mg, 150 mg, and 300 mg, though 150 mg showed the strongest sleep benefit.
Since insomnia and depression frequently travel together, a medication that addresses both can be appealing. Researchers have recommended an initial dosage of 50 to 150 mg per day for people with depression or anxiety who also have sleep problems, particularly older adults. The sedation comes from the drug’s strong activity at histamine receptors, which are the same receptors targeted by over-the-counter sleep aids, though quetiapine is far more potent.
Immediate-Release vs. Extended-Release
Seroquel comes in two forms: immediate-release (IR) tablets taken once or twice daily, and extended-release (XR) tablets taken once at bedtime. For depression, the extended-release version is generally preferred. A randomized, double-blind crossover study found that patients on the XR form reported significantly less daytime sedation than those on IR, along with better overall treatment satisfaction and milder side effects. Cognitive performance was the same between the two forms.
The practical difference is timing. The IR version releases the drug quickly, causing a strong wave of sedation that can linger into the next day. The XR version spreads absorption out, reducing that morning grogginess. If you’re taking quetiapine for depression and finding that daytime drowsiness is a problem, the extended-release version is worth discussing.
Weight Gain and Metabolic Changes
Weight gain is one of the most common concerns with Seroquel, and the data confirms it’s a real issue. The immediate-release form is associated with three to nearly six pounds of weight gain on average, with the effect plateauing at a certain dose rather than increasing indefinitely. The extended-release form follows a slightly different pattern, with initial weight gain at low doses that stabilizes at higher ones.
More concerning than the number on the scale, even low doses of quetiapine have been linked to significant metabolic changes, including shifts in blood sugar and cholesterol. Because of this, monitoring guidelines call for checking fasting blood sugar and cholesterol at baseline, again at 4 weeks (quetiapine is specifically flagged alongside olanzapine and clozapine for early lipid checks), and then at 12 weeks. After that, weight should be tracked every three months and metabolic blood work repeated annually at minimum.
Safety Warnings for Younger Adults
Seroquel carries a black box warning, the FDA’s most serious label, regarding suicidal thoughts and behavior in young people. In pooled clinical trials, patients under 18 had 14 additional cases of suicidal thinking per 1,000 people treated compared to placebo. For adults aged 18 to 24, that number was 5 additional cases per 1,000. In adults 25 to 64, there was actually one fewer case compared to placebo, and in those 65 and older, six fewer cases.
This warning applies to all medications used for depression, not just quetiapine. The risk is highest during the first few months of treatment and during dose changes. Symptoms to watch for include new or worsening anxiety, agitation, panic attacks, irritability, hostility, impulsivity, and restlessness.
Stopping Seroquel Safely
Quetiapine should not be stopped abruptly, even at doses as low as 25 mg. Discontinuation can cause rebound insomnia, emotional instability, irritability, and sensory overstimulation. Some people describe a general “icky” physical feeling during withdrawal. Abrupt stops carry the additional risk of psychiatric relapse.
Tapering is typically done over several weeks to months, with gradual dose reductions. A common approach involves cutting the dose in half for a period, then reducing further over time. Even people on very low doses (25 mg) have reported needing to chip away at their dose in quarter-tablet increments over the course of weeks before discontinuing entirely. The slower and more gradual the taper, the smoother the transition tends to be.